Martin Munte Email & Phone Number

Zürich , Switzerland , Ch

Vaccentis AG is a clinical-stage Swiss biopharmaceutical company developing patient-specific medicines to improve patients’ chances of recovery from chronic and malignant diseases. Vaccentis’ product pipeline includes VCC-001, Autologous Serum Eye Drops (ASAT), Individual Immunotherapy, and Urexent®. VCC-001 is in clinical development to treat non-metastatic renal cell carcinomas; prepared from the patients’ tumors, it stimulates the immune system to attack tumor cells and reduces the risk of recurrence and metastases. ASAT is an efficient treatment of dry eye diseases prepared from the patient’s blood. Research suggests it may be more effective and better tolerated than traditional tear replacement products.

SCOPE OF SERVICES:STRATEGIC ASSESSMENTS AND PLANS• Macroeconomic analysis - health care environment• Strategy and portfolio assessment • Scenario analysis and impact assessments• Go-to-market launch models • Growth strategy plans – Innovative and BiosimilarsORGANIZATIONAL EXCELLENCE & EFFECTIVENESS• Headquarter and Affiliates: Marketing & Sales, Government Affairs, Policy, Access, Regulatory and Pricing o Responsibilities, communication and collaboration o Integrative planning and execution o Commercial excellence: Digital innovation & multi channel • Governance for successful product launches & defencePERFORMANCE MANAGEMENT - PROGRAMM AND INTERIM MANAGEMENT• Government Affairs & External Engagement plans• Business plan execution (Milestone/ KPI tracking)• Business case/business development support• Dedicated project management• P&L (Turnaround) managementORGANIZATIONAL CHANGE JOURNEYS • Culture development, milestone tracking, talent retention ESTABLISHMENT AND MANAGEMENT OF PARTNERSHIPS• Pharma/Biotech: KOLs, Payors, Government stakeholders

Thousand Oaks, Ca, Us

Leading all European Policy, Government Affairs and Professional Associations efforts for EU-Stakeholder and Business management to achieve optimal Access• Implementing key Policy activities and changes to shape the Access Environment and to enable optimal Access for the Amgen Brand, Biosimilar and Pipeline products • Provide strategic and tactical advice based on key Policy Priorities for affiliates • Develop/ collect and provide policy material to regional brand teams and affiliates • Lead or support related activities/ projects (as part of a cross-functional team) • Identification of EU policy trends and priorities • Set up/ orchestrate activities to shape future policies and budgets on the EU level together with industry organizations and individually in collaboration with affiliates

Thousand Oaks, Ca, Us

115 Employees, 120 $M sales • Managing Director with full P&L responsibility and Executive Director under trade law • All product launches successfully reimbursed with optimal patient access from 2009 to 2019 • Sales doubled and profit tripled in period • New indications launched: Bone, Cardio, Biosimilars with MS leadership

Thousand Oaks, Ca, Us

45 employees, 45 $M sales • Successful reimbursement and launch for innovative products• Highest MS for Bone in Europe

Thousand Oaks, Ca, Us

60 Amgen + 1400 MN employees • Sales turnaround from 20 $M to 60 $M • Built up of Amgen Oncology business, fostered the MN integration, reintegration of GCSF business from Roche and launch of innovative Amgen products • Led Amgen Turkey to its first year of profit (from -12 $M to +20 $M)

Cambridge, Cambridgeshire, Gb

• Member of the Leadership team, Executive Secretary • Direct P&L Responsibility for Oncology and CNS Business Units

Cambridge, Cambridgeshire, Gb

• Member of the Leadership team, Executive Secretary • Responsible for Market Access, Regulatory and Business Development & Pricing

Cambridge, Cambridgeshire, Gb

• Head of Marketing Cardiovascular, Gastrointestinal, Respiratory and Hospital • Leadership, Coaching and Development of 17 Managers within the Marketing Primary Care Department

Switzerland 🇨🇭 , Ch

• Cardio/Osteoporosis Region East/South • Leadership, Coaching and Development of 9 Field Representatives

Switzerland 🇨🇭 , Ch

• Responsible for the Launch of the neuraminidase inhibitor Tamiflu for Influenza, for Infection and Anaesthesia

Cambridge, Cambridgeshire, Gb

• Project Manager for the new AstraZeneca Sales Force Organization • Coordinator of the Focus Merger Project • Member of the Marketing & Sales Task Force • Member of the site selection team 05/1997 - 06/1999 Field Product Specialist Hospital • Product Management and Field Representative at the University Hospital Graz